IMRX
Immuneering Corporation Class AAbout IMRX
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Company
- Headquarters
- Cambridge, MA
- Employees
- 57 (2026)
- Listed
- Jul 30, 2021
- Exchange
- Nasdaq
- Website
- immuneering.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #217 of 429
- P/B #237 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T+3.19%
- JNJJohnson & Johnson$657.7B-0.73%
- ABBVAbbVie Inc$521.1B+1.41%
- MRKMerck & Co Inc$368.9B+2.18%
- NVSNovartis AG$305.6B-0.19%
Financial summary
Related companies
About
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.